Shares of Genmab A/S (OTCMKTS:GNMSF - Get Free Report) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $211.01 and traded as high as $214.26. Genmab A/S shares last traded at $207.54, with a volume of 859 shares trading hands.
Genmab A/S Stock Performance
The stock has a market cap of $13.74 billion, a P/E ratio of 19.99 and a beta of 1.04. The firm's fifty day simple moving average is $211.01 and its 200-day simple moving average is $237.75.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Read More
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
